[Metastatic hormone refractory prostate cancer: new treatment horizon]Daniel Keizman
Genitourinary Oncology Service, Division of Oncology, Meir Medical Center, Sackler Faculty of Medicine, Tel Aviv University
Harefuah 151:545-9, 555, 554. 2012
..This review will focus on recent advances in the standard treatments paradigm in mHRPC...
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogramDaniel Keizman
Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel
Oncologist 17:1508-14. 2012
..We assessed the association between the pretreatment NLR and outcome of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the CYP17 inhibitor ketoconazole...
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinomaDaniel Keizman
Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Israel
Eur J Cancer 48:1031-7. 2012
....
- The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma
Daniel Keizman
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Eur J Cancer 48:202-8. 2012
..Sunitinib is a standard treatment for metastatic renal cell carcinoma (mRCC). The neutrophil to lymphocyte ratio (NLR), an index of systemic inflammation, is associated with outcome in several cancer types...
- Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression
Daniel Keizman
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
Prostate 72:461-7. 2012
....
- Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination
Daniel Keizman
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
Eur J Cancer 47:1955-61. 2011
..Data suggests that they may inhibit tumourigenesis...
- Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study
Daniel Keizman
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
Clin Cancer Res 16:5269-76. 2010
..To evaluate the safety and activity of 6 months of treatment with lenalidomide at 5 or 25 mg/d in nonmetastatic biochemically relapsed prostate cancer...
- An animal model for chemotherapy-associated steatohepatitis and its prevention by the oral administration of fatty acid bile acid conjugate
Daniel Keizman
Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Cancer 116:251-5. 2010
..The current study was designed to establish an animal model of CASH and to use that model to study the effect of FABACs on its occurrence...
- Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis
D Keizman
Department of Oncology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Acta Neurol Scand 119:383-9. 2009
..To prospectively determine the intensity of systemic low-grade inflammation in patients with amyotrophic lateral sclerosis (ALS)...
- Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress?
D Keizman
Department of Internal Medicine H, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
J Neurol Sci 285:95-9. 2009
..The objective of this study was to prospectively determine the serum uric acid levels in ALS patients and allegedly healthy individuals and to correlate those values with measures of ALS disease progression among the patients...
- The clinical significance of bile duct sludge: is it different from bile duct stones?
D Keizman
Department of Gastroenterology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Surg Endosc 21:769-73. 2007
..This study aimed to compare BDS with bile duct stones in terms of frequency, associated risk factors, and clinical outcome after endoscopic therapy...
